Cantor Fitzgerald Sticks to Its Buy Rating for Evolus Inc (EOLS)


Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Evolus Inc (EOLS) today and set a price target of $35. The company’s shares closed on Friday at $14.91.

Chen noted:

“Based on our diligence, dermatologists and plastic surgeons appreciate the value proposition of Evolus’s botulinum toxin as a nearly identical product to market leader Botox sold at a discount. Therefore, we think Jeuveau could pick up meaningful market share if it is approved. and other potential upcoming catalysts should drive EOLS shares higher. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our $35 12-month price target.”

According to TipRanks.com, Chen is a 4-star analyst with an average return of 5.6% and a 35.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Evolus Inc with a $30 average price target.

See today’s analyst top recommended stocks >>

Based on Evolus Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $11.83 million. In comparison, last year the company had a net profit of $4.45 million.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EOLS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Evolus, Inc. is a medical aesthetics company. The company is engaged in providing physicians and patients with expanded choices in aesthetic procedures and treatments. Evolus was founded in November, 2012 and is headquartered in Irvine, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts